Data showed that people with type 2 diabetes using GLP-1s with FreeStyle Libre had a greater improvement in HbA1c compared to GLP-1s alone. Abbott presented the findings at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Florence, Italy.
GLP-1 receptor agonists, like Ozempic and Wegovy, provide therapy for diabetes and weight loss. This therapeutic class, a glucagon-like peptide 1, has proven to lead to improved blood sugar control and weight loss. The drug class continues to grow in popularity with prescriptions for type 2 diabetes increasing.
Last year, BTIG analysts spoke with an expert, determining the potential impact of GLP-1s on the diabetes market. Not long after, Abbott shared real-world data highlighting GLP-1s as a potential accelerator for its FreeStyle Libre CGM product family.
Today, the company added more real-world data to back up the potential for the pairing of CGM with the drug class.
Get the full story at our sister site, Drug Delivery Business News.